// App-Quantinova.ai

: In Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL), Age-Adapted Chemotherapy Intensity and MRD-Driven Transplant Indication Significantly Reduces Treatment-Related Mortality (TRM) and Improves Overall Survival - Results from the Graall-2014 Trial

Researchers

Presenter

  • Nicolas Boissel

Principal Investigators

  • Thibaut Leguay

  • Hunault-Berger Mathilde

  • Carlos Graux

  • Yves Chalandon

  • Eric Delabesse

  • Yosr Hicheri

  • Patrice Chevallier

  • Marie Balsat

  • Cedric Pastoret

  • Martine Escoffre-Barbe

  • Florence Pasquier

  • Jean-Pierre Marolleau

  • Anne Thiebaut-Bertrand

  • Anne Huynh

  • Nathalie Dhedin

  • Emilie Lemasle

  • Caroline Bonmati

  • Sebastien Maury

  • Gaelle Guillerm

  • Anna Berceanu

  • Urs Schanz

  • Thomas Cluzeau

  • Pascal Turlure

  • Philippe Rousselot

  • Bernard J.M. De Prijck

  • Nathalie Grardel

  • Marie C Bene

  • Marine Lafage

  • Norbert Ifrah

  • Veronique Lheritier

  • Vahid Asnafi

  • Emmanuelle Clappier

  • Herve Dombret

Medical Centers

  • Service Hematologie, Centre Hospitalier Lyon Sud, Lyon, France

  • Hematology Laboratory, AP-HP, Hôpital Saint-Louis, Paris, France

  • Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA

  • Gustave Roussy, Département clinique d'hématologie, INSERM UMR, Villejuif, FRA

  • Hematology Department, Centre Hospitalier de Versailles, LE CHESNAY CEDEX, France

  • INSERM U /Hematology Laboratory, University Hospital of Rennes, RENNES, FRA

  • Department of Genetics, La Timone Hospital, Aix Marseille University, MARSEILLE, France

  • Laboratory of Hematology, Centre Hospitalier Universitaire Lille, Lille, France

  • Service D'Hématologie, Centre Hospitalier Universitaire De Nancy, Nancy, FRA

  • Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland

  • department of hematology, CHU Angers, Angers, France

  • Hematology Clinic, Bordeaux University Hospital, Pessac, France

  • Department of Hematology, Université Côte d'Azur, Centre Hospitalier Universitaire, Nice, France

  • Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), Centre Hospitalier Lyon Sud, Lyon, France

  • Service d'Hématologie clinique, Hôpitaux universitaires Henri-Mondor (AP-HP), Créteil, FRA

  • Hematology Department, Henri-Becquerel Cancer Center, Rouen, France

  • CHU Sart Tilman, Liege, BEL

  • N/A, N/A, FRA

  • Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

  • Department of Clinical Hematology, Limoges University Hospital, Limoges, France

  • Université Catholique de Louvain, CHU UCL Namur (Godinne), Yvoir, Belgium

  • Clinical Hematology, Besançon University Hospital, Besançon, France

  • Laboratory of Onco-Hematology, Necker University Hospital, Paris, France

  • St-Louis Hospital, APHP, Adolescents and Young Adults Hematology Department, Paris, France

  • Department of Hematology, CHU-Grenoble Onco-Hematologie, Grenoble, France

  • Hematology Biology, Nantes University Hospital, Nantes, France

  • Clinical Hematology, Angers University Hospital, Angers, France

  • Departement d'Hematologie, Institut Paoli-Calmettes, MARSEILLE, France

  • URP-, Saint-Louis Research Insitute, Université Paris Cité, Paris, France

  • URP-, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France

  • INSERM U, Université Paris Descartes Sorbonne Cité, Paris, France

  • Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France

  • Department of Hematology, Brest University Hospital, Brest, France

  • Geneva University Hospitals, Geneva, Switzerland

  • Hôpital de Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France

  • Hematology Department, Amiens University Hospital, Amiens, France

Locations

  • France

  • Switzerland

  • United States

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Blinatumomab

  • Nelarabine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved